For the first quarter of 2026, analysts expect CVS Health to report consensus revenue of approximately $94.37 billion and adjusted EPS of $2.21, as the stock trades near $82.01 against an average price target of $95.05.
Investors are laser-focused on the Medical Benefit Ratio (MBR) as a barometer for margin recovery within the company's critical Medicare Advantage segment.
Analysts anticipate that growth in Health Services will help mitigate persistent medical cost pressures in the Health Care Benefits unit. However, market participants remain cautious regarding the impact of recent labor strike authorizations and the long-term outlook for Medicare reimbursement rates.